Mocaciclib not checked

Qurient Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
How it’s given
“The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter”In the company’s words, NCT05394103 on ClinicalTrials.gov
Tested for
Advanced Cancer, Metastatic Cancer
Main trialPhase 1/2
“Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab”In the company’s words, NCT05394103 on ClinicalTrials.gov

Other drugs for Advanced Cancer

All 2440 drugs for Advanced Cancer

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 31 Mar 2029 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mocaciclib

Following is part of Solo: you see every change to Mocaciclib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in